The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
News & Analysis: Greenwich LifeSciences, Inc.
The drop came despite the clinical-stage biotech announcing good news over the weekend.
The company reported positive data for its cancer immunotherapy candidate GP2.
Investors cheered an important new hire.
A lot of buzz-generating IPOs have more than tripled in 2020, but you probably don't know the top U.S. debutante that has soared 583% this year.
The company announced the pricing of a public offering of common stock.
Greenwich LifeSciences made investors rich overnight. Is there any growth left in this breast cancer treatment developer?